Regorafenib for Metastatic Colorectal Cancer: An Analysis of a
Registry-Based Cohort of 555 Patients

J 2020

Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients

NOVAKOVA-JIRESOVA, Alena, Katerina KOPECKOVA, Ludmila BOUBLIKOVA, Renata CHLOUPKOVÁ, Bohuslav MELICHAR et. al.

Základní údaje

Originální název

Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients

Autoři

NOVAKOVA-JIRESOVA, Alena (203 Česká republika), Katerina KOPECKOVA (203 Česká republika), Ludmila BOUBLIKOVA, Renata CHLOUPKOVÁ (203 Česká republika, domácí), Bohuslav MELICHAR (203 Česká republika), Lubos PETRUZELKA (203 Česká republika), Jindrich FINEK (203 Česká republika), Ondrej FIALA (203 Česká republika), Peter GRELL (203 Česká republika), Stanislav BATKO (203 Česká republika), Zdenek LINKE (203 Česká republika), Igor KISS (203 Česká republika), Jana PRAUSOVA (203 Česká republika) a Tomáš BÜCHLER (203 Česká republika, garant)

Vydání

CANCER MANAGEMENT AND RESEARCH, ALBANY, DOVE MEDICAL PRESS LTD, 2020, 1179-1322

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nový Zéland

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.989

Kód RIV

RIV/00216224:14110/20:00116154

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.2147/CMAR.S255332

UT WoS

000548281000003

Klíčová slova anglicky

colorectal cancer; regorafenib; registry; survival; outcome analysis

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 8. 2020 08:30, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

Citovat

NOVAKOVA-JIRESOVA, Alena, Katerina KOPECKOVA, Ludmila BOUBLIKOVA, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Lubos PETRUZELKA, Jindrich FINEK, Ondrej FIALA, Peter GRELL, Stanislav BATKO, Zdenek LINKE, Igor KISS, Jana PRAUSOVA a Tomáš BÜCHLER. Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients. CANCER MANAGEMENT AND RESEARCH. ALBANY: DOVE MEDICAL PRESS LTD, 2020, roč. 12, č. 2020, s. 5365-5372. ISSN 1179-1322. Dostupné z: https://dx.doi.org/10.2147/CMAR.S255332.

@article{1673717,
   author = {NovakovaandJiresova, Alena and Kopeckova, Katerina and Boublikova, Ludmila and Chloupková, Renata and Melichar, Bohuslav and Petruzelka, Lubos and Finek, Jindrich and Fiala, Ondrej and Grell, Peter and Batko, Stanislav and Linke, Zdenek and Kiss, Igor and Prausova, Jana and Büchler, Tomáš},
   article_location = {ALBANY},
   article_number = {2020},
   doi = {http://dx.doi.org/10.2147/CMAR.S255332},
   keywords = {colorectal cancer; regorafenib; registry; survival; outcome analysis},
   language = {eng},
   issn = {1179-1322},
   journal = {CANCER MANAGEMENT AND RESEARCH},
   title = {Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients},
   url = {https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1597040957_5f30e93d90283/cmar-255332-regorafenib-for-metastatic-colorectal-cancer-an-analysis-of.pdf},
   volume = {12},
   year = {2020}
}

TY  - JOUR
ID  - 1673717
AU  - Novakova-Jiresova, Alena - Kopeckova, Katerina - Boublikova, Ludmila - Chloupková, Renata - Melichar, Bohuslav - Petruzelka, Lubos - Finek, Jindrich - Fiala, Ondrej - Grell, Peter - Batko, Stanislav - Linke, Zdenek - Kiss, Igor - Prausova, Jana - Büchler, Tomáš
PY  - 2020
TI  - Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
JF  - CANCER MANAGEMENT AND RESEARCH
VL  - 12
IS  - 2020
SP  - 5365-5372
EP  - 5365-5372
PB  - DOVE MEDICAL PRESS LTD
SN  - 11791322
KW  - colorectal cancer
KW  - regorafenib
KW  - registry
KW  - survival
KW  - outcome analysis
UR  - https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1597040957_5f30e93d90283/cmar-255332-regorafenib-for-metastatic-colorectal-cancer-an-analysis-of.pdf
L2  - https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1597040957_5f30e93d90283/cmar-255332-regorafenib-for-metastatic-colorectal-cancer-an-analysis-of.pdf
N2  - Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.
ER  -

NOVAKOVA-JIRESOVA, Alena, Katerina KOPECKOVA, Ludmila BOUBLIKOVA, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Lubos PETRUZELKA, Jindrich FINEK, Ondrej FIALA, Peter GRELL, Stanislav BATKO, Zdenek LINKE, Igor KISS, Jana PRAUSOVA a Tomáš BÜCHLER. Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients. \textit{CANCER MANAGEMENT AND RESEARCH}. ALBANY: DOVE MEDICAL PRESS LTD, 2020, roč.~12, č.~2020, s.~5365-5372. ISSN~1179-1322. Dostupné z: https://dx.doi.org/10.2147/CMAR.S255332.

Podrobný výpis o publikaci